Interventional radiology is a field grounded in the use of advanced imaging techniques to guide minimally invasive procedures. By integrating angiography and CT in one location, clinicians at the Huntsman Cancer Institute can now perform comprehensive diagnostic and therapeutic interventions with unprecedented efficiency and accuracy. The dual imaging capabilities facilitate a seamless workflow where patients no longer need to be transferred between different rooms or make repeated visits for separate imaging sessions, significantly mitigating the logistical challenges and health risks associated with traditional workflows.

Angiography, a pivotal component of this suite, employs live X-ray fluoroscopy combined with a contrast agent injected into the blood vessels. This technique allows physicians to visualize the precise vascular feeding patterns of tumors. Recognizing the intricate vascular supply to malignant tissues is critical for therapies aimed at starving tumors by occluding their blood flow or delivering targeted chemotherapy or radiation directly via the bloodstream. This goal-driven approach maximizes the therapeutic effect on the tumor while sparing the surrounding healthy tissues, thereby minimizing the systemic side effects commonly seen in traditional systemic treatments like hair loss, nausea, and generalized toxicity.

Parallel to angiography, CT imaging offers high-resolution, still images that provide detailed anatomical information. Within the angio-CT suite, CT scans are instrumental in delineating the tumor’s exact location and its spatial relationship to adjacent organs. This precision facilitates interventions such as biopsy needle guidance and ablation therapies. Interventional radiologists employ CT to direct thermal ablation tools that either freeze (cryoablation) or heat (radiofrequency or microwave ablation) malignant cells, thereby destroying the tumor tissue with minimal collateral damage. This combined approach enhances clinical outcomes, particularly for tumors in anatomically challenging regions like the liver and kidneys.

Historically, performing angiography and CT-guided interventions required separate sessions or at least relocating patients between different suites, often under anesthesia, which increased patient discomfort, procedural risk, and health system costs. By housing both modalities in a single suite, the Huntsman Cancer Institute minimizes exposure to multiple anesthetic events and reduces time delays between imaging and treatment. This streamlined process allows clinicians to first use CT imaging to plan the intervention, proceed with the angiographic procedure under real-time X-ray guidance, and then immediately verify treatment efficacy via CT—all within the same setting.

Dr. Wael Saad, director of interventional radiology, emphasizes how the integrated suite enables dynamic imaging workflows. For example, clinicians can confirm the success of tumor embolization by analyzing post-procedure CT images before concluding the session. This capability ensures immediate adjustments if necessary, enhancing treatment precision and reducing the need for subsequent interventions. Such technological integration is set to revolutionize the treatment paradigm, especially for patients living in rural or underserved areas who would otherwise face burdensome travel and delayed follow-up.

The anatomical accuracy and real-time feedback provided by the angio-CT suite also improve multidisciplinary care coordination. Complex cancer cases often require the expertise of multiple specialists, including oncologists, radiologists, and surgeons. The hybrid imaging suite fosters collaborative treatment planning by furnishing comprehensive imaging data that inform decisions about the most appropriate minimally invasive therapies. Consequently, it accelerates therapeutic delivery and aligns with patient-centered care principles.

From a patient perspective, the reduction in procedural frequency, cumulative anesthesia exposure, and travel demands translate into improved safety, convenience, and overall experience. Patients who may have previously required separate visits spaced days or weeks apart can now complete critical imaging and treatment in a single appointment. This efficiency mitigates the emotional and physical toll associated with cancer treatment and provides timely feedback regarding therapeutic response, crucial elements in managing aggressive malignancies.

This angio-CT innovation particularly benefits liver and renal cancers, where targeted embolization and thermal ablation have emerged as vital therapeutic modalities. However, the suite’s capabilities extend across multiple cancer types, underscoring its versatility within interventional oncology. By enabling precise mapping and treatment of tumors in situ, the technology supports enhanced tumor control while preserving organ function and patient quality of life.

The implementation of the angio-CT suite embodies Huntsman Cancer Institute’s commitment to integrating cutting-edge technology with compassionate, patient-centered care. Dr. Charles Ray, interim chair of the Department of Radiology, characterizes this advancement as a “game changer” that elevates the standard of care through highly targeted therapies delivered with exceptional precision. This aligns with the institute’s strategic goal to pioneer minimally invasive approaches that improve clinical outcomes while reducing treatment-associated morbidity.

Officially launched on November 11, the angio-CT suite marks a significant investment in oncologic innovation for the Mountain West region. The novel application of dual imaging modalities in a single clinical space underscores the evolving role of interventional radiology in cancer treatment and symbolizes a promising future where technology and human expertise converge to redefine patient care standards.

Huntsman Cancer Institute, designated as a National Cancer Institute Comprehensive Cancer Center, serves patients across Utah, Idaho, Montana, Nevada, and Wyoming. The institute’s extensive research and clinical trials infrastructure supports ongoing innovation in cancer treatment, including the development of technologies like the angio-CT suite. By continuously expanding its capabilities, Huntsman advances a mission centered on transforming cancer diagnosis, treatment, and survivorship through scientific discovery and precision medicine.

In summary, the angio-CT suite at the University of Utah’s Huntsman Cancer Institute represents a pivotal advancement in the field of interventional oncology. By harnessing the synergistic power of angiography and CT imaging, the suite not only optimizes therapeutic efficacy but also significantly enhances the patient experience. This innovative model stands as a beacon for other institutions seeking to redefine cancer care through technology-driven, patient-focused solutions.

Subject of Research: Cancer treatment, interventional radiology, angiography, CT imaging

Article Title: Huntsman Cancer Institute Unveils Region’s First Integrated Angiography-CT Suite to Revolutionize Cancer Care

News Publication Date: November 11, 2023

Web References:

• https://healthcare.utah.edu/huntsmancancerinstitute/
• https://healthcare.utah.edu/radiology/interventional

Image Credits: Huntsman Cancer Institute

Keywords: Cancer treatments, Liver cancer, Interventional radiology, Angiography, CT imaging, Minimally invasive therapy, Tumor embolization, Thermal ablation

Proton therapy represents a significant leap forward in radiation oncology, diverging fundamentally from conventional photon-based radiotherapy by using charged particles—protons—to eradicate cancerous cells. The key technical advantage of proton therapy lies in the Bragg peak phenomenon, where protons deposit the majority of their energy at a specific depth corresponding to the tumor site, thereby sparing adjacent healthy tissues and vital organs from unnecessary radiation exposure. This precision minimizes collateral damage and reduces severe side effects, a crucial consideration particularly for pediatric patients and tumors located near critical structures such as the brain and spinal cord.

The impending construction encompasses an approximately 9,000-square-foot, three-story cement vault meticulously engineered to house the intricate machinery and shielding required for proton beam generation and delivery. Strategically positioned adjacent to the existing unit on the University of Utah campus, this expansion is poised to enhance the center’s treatment throughput dramatically. Amit Maity, MD, PhD, FASTRO, professor and chair of the Department of Radiation Oncology, emphasizes how this growth will widen access to proton therapy, enabling Huntsman to transcend previous patient volume constraints and extend the therapy to a broader spectrum of cancer types.

Currently, the center has maintained a delicate balance by limiting proton therapy to select indications, largely dictated by the singular vault’s operational bandwidth. The additional vault will alleviate these restrictions, offering flexibility to manage increased patient inflow and explore multidisciplinary collaborations with regional medical affiliates. This growth is expected to catalyze research and clinical trials aimed at expanding proton therapy’s indications beyond pediatric tumors and central nervous system malignancies into complex cancers such as head and neck, breast, and potentially other solid tumors.

Clinically, proton therapy is distinct in its capacity to conform the radiation dose to the three-dimensional contours of a tumor with remarkable fidelity. Unlike photon beams which deposit energy along their path—often irradiating healthy tissues before and after the target—protons halt abruptly upon delivering their therapeutic dose. This dosimetric superiority translates into measurable benefits, including reduced risks of secondary malignancies and chronic toxicities. For pediatric oncology, where patients have a lifetime ahead and heightened sensitivity to radiation effects, proton therapy’s targeted approach is invaluable.

Since its inauguration, the Huntsman Proton Therapy Center has demonstrated success in treating a diverse patient cohort, including roughly one-third pediatric cases. The current expansion mirrors a broader national trend recognizing proton therapy’s transformative potential. Notably, the United States hosts only 46 such centers, a relatively limited network given the prevalence of cancer and the therapy’s growing endorsement in clinical guidelines. The closest alternative proton centers to Salt Lake City are located in Phoenix, Seattle, and San Diego—facilities often overwhelmed by referral overflow from the Mountain West.

This geographic scarcity imposes significant logistic and financial burdens on patients, who frequently face grueling travel distances and fragmented care coordination. The new vault’s capacity promises to mitigate these challenges by offering localized advanced radiation treatment, reducing patient displacement, and bolstering kontinuität in multidisciplinary oncology management. This model aligns with Huntsman’s mission to deliver cutting-edge care within the communities it serves, fostering equity and accessibility in cancer treatment.

Matthew Poppe, MD, clinical director of the Proton Therapy Center and an investigator at Huntsman, outlines how doubling treatment availability will democratize access to this technology, allowing more patients with nuanced clinical presentations to benefit. The newly constructed vault will be outfitted with next-generation proton delivery systems, including pencil beam scanning, that facilitate intensity-modulated proton therapy (IMPT). This allows for even greater precision, accounting for tumor motion and anatomical changes over the course of treatment through sophisticated treatment planning algorithms and adaptive radiotherapy protocols.

From an operational perspective, the vault’s construction is an intricate engineering feat, requiring extensive radiation shielding, vibration isolation, and environmental controls to ensure equipment stability and patient safety. Such infrastructure is essential to the maintenance of beamline integrity and the accurate delivery of prescribed dose distributions. Furthermore, integration with the hospital’s electronic medical record and imaging systems enhances real-time treatment adaptation and quality assurance.

Mary Beckerle, PhD, CEO of Huntsman Cancer Institute, affirms that the investment underscores the center’s leadership in innovation and patient-centric care. The upcoming facility not only exemplifies technical excellence but also symbolizes a commitment to the comprehensive needs of cancer patients, emphasizing hope, healing, and transformative outcomes. Construction is slated for completion within two and a half years, setting the stage for an era in which the Mountain West can stand alongside other major metropolitan centers offering world-class proton therapy.

As Huntsman expands its proton therapy capabilities, the broader oncology community watches closely, anticipating novel clinical trials and translational research initiatives integrating molecular profiling, radiobiology insights, and advanced imaging modalities. Such endeavors aim to refine patient selection criteria, maximize therapeutic ratio, and elucidate mechanisms of proton-induced tumor control. Ultimately, this expansion may pave the way for personalized radiation oncology paradigms tailored to individual tumor biology and microenvironment dynamics.

In conclusion, the Huntsman Cancer Institute’s commitment to doubling its proton therapy capacity is more than an infrastructure upgrade—it is a decisive stride toward regional leadership in cutting-edge cancer treatment. By enhancing precision radiation therapy access, the institute advances the frontier of oncologic care, reducing side effects, improving quality of life, and fostering hope for countless patients and families across the Mountain West.

Subject of Research: Expansion of proton therapy capacity and application at Huntsman Cancer Institute
Article Title: Transforming Cancer Care in the Mountain West: Expansion of Proton Therapy at Huntsman Cancer Institute
News Publication Date: Not explicitly stated in the source
Web References:

• https://healthcare.utah.edu/huntsmancancerinstitute/
• https://healthcare.utah.edu/huntsmancancerinstitute/treatment/proton-therapy
• https://proton-therapy.org/
  Image Credits: Credit: Huntsman Cancer Institute
  Keywords: Cancer, Brain cancer, Proton therapy, Radiation oncology, Pediatric cancer, Precision medicine